Skip to content

Safety and Efficacy of P-ESWL and ERCP

Safety and Efficacy of Extracorporeal Shock Wave Lithotripsy and Endoscopic Retrograde Cholangiopancreatography for Pancreatic Stones

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05916547
Enrollment
2071
Registered
2023-06-23
Start date
2023-06-01
Completion date
2024-05-01
Last updated
2024-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Duct Stone

Keywords

Pancreatic Duct Stone, Pancreatic extracorporeal shock wave lithotripsy, Safety, Efficacy, endoscopic retrograde cholangiopancreatography

Brief summary

To determine the types, incidence and risk factors of adverse events after pancreatic extracorporeal shock wave lithotripsy (P-ESWL) and endoscopic retrograde cholangiopancreatography (ERCP), define the grading criteria of adverse events after P-ESWL and ERCP, and analyze the efficacy of P-ESWL and ERCP, which will provide evidence-based medical evidence to guide physicians' clinical practice.

Detailed description

Currently, pancreatic extracorporeal shock wave lithotripsy (P-ESWL) and endoscopic retrograde cholangiopancreatography (ERCP) has become the preferred treatment for pancreatic duct stones. Although some studies had confirmed the safety and efficacy of P-ESWL and ERCP, the sample size were small and the follow-up period were short. Therefore, investigators designed this study with a large sample and a long follow-up period to clarify the efficacy and safety of P-ESWL and ERCP, so as to guide clinical work, standardize the diagnosis and treatment process of adverse events.

Interventions

PROCEDUREpancreatic extracorporeal shock wave lithotripsy

Pancreatic extracorporeal shock wave lithotripsy is based on the principle of shock wave energy. Whenever energy is abruptly released in an enclosed space, shock waves are generated and then cross to the surface of pancreatic duct stones to cause further fragmentation.

Sponsors

Changhai Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients hospitalized in Changhai Hospital from 2011.03.01 to 2018.06.30. * Painful patients with chronic pancreatitis. * Patients who completed pancreatic extracorporeal shock wave lithotripsy.

Exclusion criteria

* Patients who diagnosed pancreatic cancer within 2 years after diagnosing chronic pancreatitis. * Patients who refused to participate in the study.

Design outcomes

Primary

MeasureTime frameDescription
the incidence of post-ESWL adverse events1 monthsAn adverse event of P-ESWL is classified as either a complication or a transient adverse event (TAE), depending on severity. Complications are recognized as adverse events needing specific medical intervention and prolonged hospitalization, while TAEs are defined as transient injuries caused by shock waves, which required no medical intervention and do not prolong hospitalization.

Secondary

MeasureTime frameDescription
the rate of pancreatic duct clearance1 weekComplete clearance: more than 90% clearance of stone volume; partial clearance: 50% to 90% clearance of stone volume; unsuccessful clearance: failure to fragment the stones to less than 3 mm diameter or less than 50% clearance of stone volume.
Pain relief of patients after P-ESWL and ERCPmore than 24 monthsThe ratio of patients with complete pain relief (an Izbicki pain score was ≤ 10), partial relief (an Izbicki pain score \> 10 with a decrease of \> 50%) and no relief.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026